Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.32 USD | +10.55% | +4.76% | -22.81% |
Valuation
Fiscal Period: April | 2019 | 2020 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Capitalization 1 | 54.12 | 53.62 | 168.3 | 86.92 | 47.55 | - | - |
Enterprise Value (EV) 1 | 54.12 | 53.62 | 168.3 | 86.92 | 47.55 | 47.55 | 47.55 |
P/E ratio | - | - | - | -3.19 x | -3.76 x | -5.1 x | -11.2 x |
Yield | - | - | - | - | - | - | - |
Capitalization / Revenue | 4.95 x | 3.81 x | 8.67 x | 4.21 x | 1.93 x | 1.59 x | 1.31 x |
EV / Revenue | 4.95 x | 3.81 x | 8.67 x | 4.21 x | 1.93 x | 1.59 x | 1.31 x |
EV / EBITDA | -13,880,319 x | 1,024,958,603 x | - | - | - | - | - |
EV / FCF | - | - | - | - | - | - | - |
FCF Yield | - | - | - | - | - | - | - |
Price to Book | - | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 13,588 | 13,848 | 23,539 | 24,965 | 26,315 | - | - |
Reference price 2 | 2.974 | 2.775 | 5.560 | 2.570 | 1.320 | 1.320 | 1.320 |
Announcement Date | 8/28/19 | 8/28/20 | 7/29/22 | 7/10/23 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: April | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | 10.93 | 14.06 | - | 19.4 | 20.66 | 24.59 | 29.82 | 36.38 |
EBITDA | -3.899 | 0.0523 | - | - | - | - | - | - |
EBIT 1 | - | -4.553 | - | -16.75 | -28.55 | -13.84 | -9.147 | -4.273 |
Operating Margin | - | -32.39% | - | -86.33% | -138.16% | -56.3% | -30.68% | -11.74% |
Earnings before Tax (EBT) 1 | - | -5.293 | - | -15.85 | -27.75 | -13.13 | -9.147 | -4.273 |
Net income 1 | - | -4.947 | -7.34 | -16.7 | -26.56 | -12.13 | -9.147 | -4.273 |
Net margin | - | -35.19% | - | -86.08% | -128.53% | -49.33% | -30.68% | -11.74% |
EPS 2 | - | - | - | - | -0.8052 | -0.3510 | -0.2590 | -0.1180 |
Free Cash Flow | - | - | - | - | - | - | - | - |
FCF margin | - | - | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - | - |
Announcement Date | 8/28/19 | 8/28/20 | 7/28/21 | 7/29/22 | 7/10/23 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: April | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 | 2025 Q3 | 2025 Q4 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | 4.7 | 4.815 | 5.2 | 4.7 | 5.2 | 5.171 | 5.621 | 5.688 | 6.15 | 6.221 | 6.53 | 6.8 | 7.4 | 7.5 | 8.1 |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBIT 1 | -4.688 | -4.307 | -4.287 | -10.07 | -7.824 | -4.58 | -6.076 | -4.177 | -3.023 | -3.34 | -3.303 | - | - | - | - |
Operating Margin | -99.74% | -89.45% | -82.44% | -214.3% | -150.46% | -88.57% | -108.09% | -73.44% | -49.15% | -53.69% | -50.58% | - | - | - | - |
Earnings before Tax (EBT) 1 | -4.819 | -3.618 | -4.369 | -9.784 | -7.477 | -4.595 | -5.897 | -3.827 | -2.59 | -3.457 | -3.253 | - | - | - | - |
Net income 1 | -5 | -3.826 | -4.644 | -9.4 | -7.351 | -4.699 | -5.13 | -3.565 | -2.622 | -2.94 | -3.003 | - | - | - | - |
Net margin | -106.38% | -79.46% | -89.31% | -200% | -141.37% | -90.87% | -91.26% | -62.68% | -42.63% | -47.26% | -45.99% | - | - | - | - |
EPS 2 | - | - | - | - | -0.2199 | -0.1382 | -0.1505 | -0.1035 | -0.0737 | -0.0814 | -0.0850 | -0.0740 | -0.0440 | -0.0590 | -0.0740 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 12/13/21 | 3/16/22 | 7/29/22 | 9/14/22 | 12/15/22 | 3/16/23 | 7/10/23 | 9/14/23 | 12/14/23 | 3/14/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: April | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - | - | - |
Net Cash position | - | - | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
Free Cash Flow | - | - | - | - | - | - | - | - |
ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - | - | - |
Cash Flow per Share 2 | - | - | - | - | -0.6000 | -0.1400 | - | - |
Capex | - | - | - | - | - | - | - | - |
Capex / Sales | - | - | - | - | - | - | - | - |
Announcement Date | 8/28/19 | 8/28/20 | 7/28/21 | 7/29/22 | 7/10/23 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-22.81% | 34.74M | |
-4.66% | 86.13B | |
+1.32% | 39.82B | |
-19.27% | 30.42B | |
+57.86% | 25.23B | |
-16.09% | 15.36B | |
-9.14% | 11.95B | |
-17.69% | 11.6B | |
-43.00% | 11.51B | |
+5.24% | 8.71B |
- Stock Market
- Equities
- IPA Stock
- Financials ImmunoPrecise Antibodies Ltd.